Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals faces steep financial hurdles despite AI‑powered drug discovery—can its high valuation survive in a loss‑making biotech market?

Recursion Pharmaceuticals’ gap‑up stock surge after analyst upgrade shows short‑term momentum, but negative earnings and mixed ratios caution investors on long‑term value.

Recursion Pharmaceuticals, a biotech company leveraging AI and automation, faces financial struggles and uncertain future despite its innovative approach to drug discovery.

Recursion Pharmaceuticals Inc. reported Q1 2025 earnings, beating estimates, but faced increased losses amid restructuring efforts, while advancing its strategic focus on oncology and rare diseases.

Recursion Pharmaceuticals reports promising results from its clinical trial of REC-4881, a potential treatment for Familial Adenomatous Polyposis (FAP), showing a 43% median reduction in polyp burden at Week 13.